Trials / Recruiting
RecruitingNCT07384013
Study Protocol: Impact of Metamizole (Optalgin®) on Anti-Xa Concentrations in Oncology Patients Receiving DOACs
Impact of Metamizole (Optalgin®) on Anti-Xa Concentrations in Oncology Patients Receiving DOACs
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Rambam Health Care Campus · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Evaluation of the Effect of metamizole (Optalgin®) on Anti-Xa Levels in Oncology Patients Receiving Direct Oral Anticoagulants (DOACs)
Detailed description
Evaluation of the Effect of metamizole (Optalgin®) on Anti-Xa Levels in Oncology Patients Receiving Direct Oral Anticoagulants (DOACs)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | metamizole | chronic metamizole use |
| DRUG | metamizole | New metamizole users |
Timeline
- Start date
- 2025-11-01
- Primary completion
- 2027-12-31
- Completion
- 2027-12-31
- First posted
- 2026-02-03
- Last updated
- 2026-02-03
Locations
1 site across 1 country: Israel
Source: ClinicalTrials.gov record NCT07384013. Inclusion in this directory is not an endorsement.